Welcome to our dedicated page for Bioxcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics filings document regulatory, financing, governance, and operating disclosures for a Nasdaq-listed biopharmaceutical company focused on AI-supported drug re-innovation in neuroscience. The company’s Form 8-K reports include IGALMI regulatory updates, business and financial results, and exhibits tied to press releases and material corporate events.
The filing record also covers registered direct offerings, common stock, pre-funded warrants and accompanying warrants, credit agreement amendments, registration rights, unregistered equity issuances, and retention or milestone-based compensation arrangements. These disclosures describe BioXcel’s capital structure, contractual obligations, Nasdaq-listed common stock, and formal updates connected to its approved IGALMI product and BXCL501 development program.
BioXcel Therapeutics Chief Scientific Officer Frank Yocca reported routine equity compensation activity and a small tax-related sale. On May 4, 2026, he exercised 17,500 Restricted Stock Units (RSUs), receiving the same number of common shares at a conversion price of $0.00 per share. The RSUs are part of a 70,000-unit grant awarded on January 1, 2026, which vests in four installments over two years, contingent on continued employment. On May 20, 2026, he sold 6,845 common shares in an open-market transaction at a weighted average price of $1.085 per share, with individual trade prices ranging from $1.07 to $1.105. The filing notes this sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on February 3, 2026 solely to cover taxes due from the RSU vesting. After these transactions, Yocca directly holds 26,175 common shares and 52,500 RSUs, indicating he retained most of the equity received from the recent vesting.
BioXcel Therapeutics, Inc. executive Javier Rodriguez reported RSU vesting and a small share sale linked to taxes. On May 4, 2026, he exercised 17,500 Restricted Stock Units into an equal number of Common Stock shares at a conversion price of $0.00 per share. A related derivative entry shows 52,500 RSUs remaining after this vesting.
On May 20, 2026, he sold 6,560 Common Stock shares in an open-market transaction at a weighted average price of $1.084 per share, with individual sale prices ranging from $1.07 to $1.09. According to the disclosure, this sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on February 3, 2026 solely to cover taxes due from the RSU vesting. Following these transactions, he directly holds 26,803 shares of Common Stock.
BioXcel Therapeutics, Inc. Chief Financial Officer Richard Steinhart reported compensation-related share activity. On May 4, 2026, he exercised 17,500 Restricted Stock Units (RSUs), receiving the same number of common shares at a conversion price of $0.00 per share. These RSUs are part of a 70,000-unit grant made on January 1, 2026, which vests 25% six months after November 4, 2025 and the remaining 75% in three equal six‑month installments.
On May 20, 2026, Steinhart sold 6,845 common shares in open-market transactions at a weighted average price of $1.085 per share, within a range of $1.07 to $1.105. According to the disclosure, this sale was executed under a Rule 10b5-1 trading plan adopted on February 3, 2026 solely to cover taxes due from the RSU vesting. After the transactions, he directly owns 26,300 common shares and continues to hold 52,500 RSUs, indicating a remaining equity stake through both shares and unvested awards.
BioXcel Therapeutics, Inc. CEO and President Vimal Mehta reported an RSU vesting and a related stock sale. On May 4, 2026, he exercised 49,758 Restricted Stock Units, receiving the same number of common shares at a stated price of $0.00 per share.
On May 20, 2026, he sold 19,419 common shares in an open-market transaction at a weighted average price of about $1.087 per share, pursuant to a Rule 10b5-1 trading plan established solely to cover taxes from the RSU vesting. After this sale, he directly held 69,598 common shares.
The filing also notes indirect holdings of 480,343 common shares by BioXcel LLC and 125 common shares held by his spouse. A prior grant of 199,032 RSUs on January 1, 2026 vests over two years from a Vesting Commencement Date of November 4, 2025, with 149,274 RSUs remaining after the reported conversion.
BioXcel Therapeutics filed a Form 144 notice relating to Common Stock. The filing records the vesting of restricted stock unit awards of 19,419 shares on 05/04/2026. The record lists 30,877,605 shares outstanding as of 05/20/2026 and identifies NASDAQ as the exchange and Merrill Lynch as the broker location.
BioXcel Therapeutics, Inc. submitted a Form 144 notice relating to a proposed sale of 6,560 shares of Common Stock. The shares are tied to the vesting of restricted stock unit awards dated 05/04/2026 and were granted as part of issuer equity compensation plan.
BioXcel Therapeutics, Inc. submitted a Rule 144 notice to sell 6,845 shares of Common Stock related to restricted stock units that vested on 05/04/2026.
The filing lists 30,877,605 shares outstanding as of 05/20/2026 and identifies the sale as tied to the vesting of RSU awards granted under the issuer's equity compensation plan.
BioXcel Therapeutics filed a Form 144 reporting the vesting and proposed sale of 6,845 shares of Common Stock. The securities are described as restricted stock unit awards that vested on 05/04/2026. The filing shows 30,877,605 shares outstanding as of 05/20/2026 on NASDAQ.
BioXcel Therapeutics reports that Armistice Capital, LLC and Steven Boyd beneficially own 1,910,076 shares of common stock, representing 7.05% of the class. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., shares voting and dispositive power over those shares.
The statement is a Schedule 13G style disclosure identifying beneficial ownership and the reporting persons; it notes the Master Fund holds the shares and that the Master Fund has the right to receive dividends or sale proceeds. The filing is signed by Steven Boyd on 05/15/2026.
BioXcel Therapeutics reported first quarter 2026 results and a key regulatory milestone. The FDA accepted a supplemental New Drug Application for IGALMI for at-home use in agitation tied to bipolar disorders or schizophrenia and set a November 14, 2026 PDUFA action date. The company is also advancing BXCL501 in late-stage trials for agitation in Alzheimer’s dementia and is evaluating strategic options with an advisor for the IGALMI franchise.
Net revenue from IGALMI was $206 (thousands) versus $168 (thousands) a year earlier. Operating expenses were $10,429 (thousands), driven mainly by $7,191 (thousands) in SG&A and $2,955 (thousands) in R&D, leading to a net loss of $12,691 (thousands), compared with $7,254 (thousands) in 2025. Cash, cash equivalents and restricted cash were $17,180 (thousands) as of March 31, 2026, and total stockholders’ equity was a deficit of $105,543 (thousands). The company notes conditions and events that raise substantial doubt about its ability to continue as a going concern.